Definition
First-pass metabolism (also called first-pass effect or presystemic metabolism) is the process by which an orally ingested drug is partially broken down by the liver before it reaches the systemic circulation. When a drug is swallowed and absorbed through the gastrointestinal tract, it travels via the portal vein directly to the liver, where enzymes metabolize a significant portion of the drug before it ever enters the general bloodstream. This process substantially reduces the amount of active drug available to produce its intended effects — a measurement known as bioavailability.
How First-Pass Metabolism Works
After oral ingestion, a drug dissolves in the stomach and small intestine and is absorbed through the intestinal wall into the portal venous system. The portal vein carries blood from the GI tract directly to the liver, the body's primary metabolic organ. In the liver, cytochrome P450 enzymes (particularly CYP3A4 and CYP2B6 in ketamine's case) chemically transform the parent drug into metabolites, which may be active, inactive, or both.
Only the fraction of drug that survives this hepatic processing enters the systemic circulation and is available to reach target organs. This concept is explored in our bioavailability guide, which compares absorption rates across all ketamine routes — including the brain. The oral bioavailability of a drug reflects how much of the ingested dose ultimately reaches the bloodstream in its active form. Drugs with extensive first-pass metabolism have low oral bioavailability, meaning a much larger oral dose is needed to achieve the same blood levels as a smaller intravenous dose.
Impact on Oral Ketamine
First-pass metabolism is the central pharmacokinetic challenge for oral ketamine formulations. When ketamine is administered intravenously, 100 percent of the dose enters the bloodstream (bioavailability of 100 percent). When taken orally, however, ketamine undergoes extensive first-pass metabolism, and only approximately 17 to 24 percent of the swallowed dose reaches systemic circulation as intact ketamine.
The liver converts ketamine primarily into norketamine via N-demethylation by CYP3A4 and CYP2B6 enzymes. Norketamine retains some pharmacological activity — roughly one-third to one-fifth the potency of ketamine at the NMDA receptor — and may contribute to the overall therapeutic effect of oral formulations. However, the substantial reduction in parent drug concentration means that oral doses must be considerably higher than IV doses to achieve comparable clinical effects.
Sublingual and Buccal Routes
To partially circumvent first-pass metabolism, ketamine is often administered as sublingual troches or buccal lozenges. When held under the tongue or against the inner cheek, ketamine is absorbed directly through the oral mucosa into the bloodstream, bypassing the portal circulation and liver. Sublingual administration increases bioavailability to approximately 25 to 30 percent — an improvement over swallowed oral ketamine, though still far below the 100 percent achieved intravenously.
In practice, some portion of a sublingual dose is inevitably swallowed with saliva and subjected to first-pass metabolism. This means sublingual bioavailability varies depending on how long the patient holds the troche in place and how much saliva is swallowed during the absorption period.
Clinical Significance
The first-pass effect has several practical implications for patients and providers:
- Dose adjustments: Oral and sublingual ketamine doses are necessarily higher than IV doses for equivalent effect, which must be accounted for in prescribing.
- Variable absorption: Individual differences in liver enzyme activity (influenced by genetics, age, other medications, and liver health) produce considerable variability in how much active ketamine reaches the bloodstream from a given oral dose.
- Active metabolites: The norketamine produced by first-pass metabolism may itself contribute therapeutic benefit, which some researchers suggest could make oral ketamine a distinct clinical entity rather than simply a less efficient version of IV ketamine.
- Drug interactions: Medications that inhibit or induce CYP3A4 and CYP2B6 can alter ketamine's first-pass metabolism, increasing or decreasing its effective bioavailability.
References
- Oral Ketamine Pharmacokinetics — Clements et al. (1982), Journal of Pharmaceutical Sciences. Early characterization of ketamine bioavailability by route.
- Bioavailability of Ketamine After Various Routes of Administration — Yanagihara et al. (2003), comprehensive review of route-dependent pharmacokinetics.
- First-Pass Effect in Clinical Pharmacology — StatPearls overview of first-pass metabolism.
Share